Koru Medical (KRMD) announced the submission of a 510(k) premarket notification to the FDA seeking clearance for the use of Koru Medical’s FreedomEDGE infusion system to subcutaneously administer Phesgo, a co-formulated therapy for HER2+ breast cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD: